Robert Thomas Fremeau Jr. - 28 Oct 2021 Form 4 Insider Report for Vyant Bio, Inc.

Role
Chief Scientific Officer
Signature
/s/ Andrew LaFrence, attorney-in-fact
Issuer symbol
N/A
Transactions as of
28 Oct 2021
Net transactions value
+$2,190
Form type
4
Filing time
17 Nov 2021, 16:05:37 UTC
Previous filing
17 Nov 2021
Next filing
17 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VYNT Common Stock, $0.0001 par value Purchase $2,190 +1,000 $2.19 1,000 28 Oct 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VYNT Stock option (right to buy) Award $0 +250,000 $0.000000 250,000 01 Nov 2021 Common Stock 250,000 $2.55 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option on November 1, 2022, and the remaining seventy five percent (75%) of the shares underlying the option shall vest in thirty six (36) equal monthly installments commencing December 1, 2022; provided that the participant remains a service provider to the Company through each applicable vesting date